Median age (IQR), years |
73 (67-76) |
Biopsy Gleason Score, n (%) |
|
≤7 |
11 (17.4) |
8 |
11 (17.4) |
≥9 |
41 (65.2) |
NA |
3 |
Prior local therapy, n (%) |
|
Presence |
19 (28.8) |
Absence |
47 (71.2) |
Measurable disease, n (%) |
46 (69.7%) |
Pain, n (%) |
30 (45.4%) |
Progression on docetaxel <6 months, n (%) |
54 (81.8) |
Number of docetaxel cycles, median (IQR) |
7 (5-10) |
Prior treatment for CRPC, n (%) |
|
Abiraterone/Enzalutamide |
56 (84.5) |
Radium-223 |
4 (6.06) |
Performance status |
|
0 |
43 (65.1%) |
1 |
15 (22.7%) |
2 |
8 (12.2%) |
Median time on hormone treatment (IQR), years |
3.54 (2.23-6.74) |
Median hemoglobin (IQR), g/dL |
12.1 (10.9-12.9) |
Median alkaline phosphatase (IQR), IU/L |
288 (204-496) |
Median PSA (IQR), ng/mL |
59.1 (18.1-176.4) |
Metastatic sites, n (%) |
Bone |
58 (87.8) |
Lymph node |
39 (59.1) |
Visceral |
18 (27.2%) |
Number of cabazitaxel cycles, median (IQR) |
5 (3-8) |